Multicenter Study of Hypofractionated Postoperative Radiotherapy in Patients Diagnosed With Prostate Carcinoma

Inclusion Criteria: * Age ≥ 18 years. * ECOG 0-1 status. * Previous radical prostatectomy (any modality will be allowed) with or without lymphadenectomy. * Histological confirmation of prostate adenocarcinoma in the prostatectomy specimen. * pT2-T3 Version 2.0, March 27, 2019 * pN0-Nx * Indication of postoperative RT: * Adjuvant RT: pT3 and / or positive margins with PSA \<0.2 ng / ml. Delayed RT is considered (\> 6 months from the date of surgery but PSA \<0.2 ng / ml). * Rescue RT: exclusive biochemical recurrence, without evidence of macroscopic local, regional or distant disease, after surgery. Biochemical recurrence is considered PSA ≥ 0.2 ng / ml after undetectable levels, confirmed with a subsequent determination. * PSA levels ≤ 2 ng / ml after, at least 45 days after surgery and 30 days before inclusion in the study. * No clinical evidence of lymph node disease. The presence will be admitted by imaging tests of pelvic nodes ≤ 1 cm in its shortest axis. * No evidence of disease in the prostatic fossa. If you doubt by digital rectal examination or CT, an MRI will be performed. * No evidence of distant disease after performing a thoraco-abdominal-pelvic CT scan and bone scan. * Reasonable follow-up possibilities. * Ability to complete the EPIC-26 questionnaire. * Written informed consent prior to inclusion in the study. Exclusion Criteria: * \- Previous pelvic radiation therapy. * Distant metastasis. * Macroscopic residual tumor. * PSA\> 2 ng / ml. * Pathological stage T4. * Lymph node involvement. * Pelvic or para-aortic nodules in the reevaluation images after surgery, except pelvic nodes ≤ 1 cm in their shortest axis. * Indication of pelvic nodal RT. Version 2.0, March 27, 2019 * Severe urinary incontinence at the time of indication for radiotherapy. * Uni / bilateral hip prosthesis * Previous tumors, except non-melanoma skin carcinoma, and which are not free of disease for at least 3 years from the end of the treatment of said neoplasms. Bladder tumors are excluded in all cases. * Genetic hyper-radio-sensitivity syndromes. * Chronic inflammatory bowel disease or partial or radical cystectomy for any reason. * Previously treated with androgen deprivation therapy for a period greater than 3 months. * Previously treated with chemotherapy for prostate cancer. * Life expectancy \<5 years or severe comorbidity: unstable angina, congestive heart failure, transmural myocardial infarction requiring admission in the last 6 months, active infectious process, respiratory disease requiring hospitalization, liver failure (Child-Pugh Class B or C), HIV with a CD4 count \<200 cells / ml, kidney failure requiring dialysis and immunosuppressed by other causes.